Compare
Edgewise Therapeutics, Inc. vs Standard Biotools Inc. vs Geron Corp vs Olema Pharmaceuticals, Inc.
| Latest fiscal year | Edgewise Therapeutics, Inc. EWTX | Standard Biotools Inc. LAB | Geron Corp GERN | Olema Pharmaceuticals, Inc. OLMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $85.33M | n/a | n/a |
| Revenue growth (YoY) | n/a | -6.2% | n/a | n/a |
| Gross margin | n/a | 49.9% | n/a | n/a |
| Operating margin | n/a | -129.2% | n/a | n/a |
| Net margin | n/a | -87.8% | n/a | n/a |
| Net income | -$167.79M | -$74.90M | -$83.50M | -$162.45M |
| EPS (Diluted) | -$1.63 | -$0.20 | -$0.13 | -$1.87 |
| Operating cash flow | -$143.82M | -$74.34M | -$111.04M | -$146.72M |
| Free cash flow | -$144.07M | -$82.65M | n/a | n/a |
| Cash & equivalents | $61.15M | $120.86M | $77.56M | $48.30M |
| Total assets | $552.60M | $567.75M | $570.54M | $533.43M |
| Total liabilities | $30.35M | $143.46M | $344.67M | $54.87M |
| Shareholders' equity | $522.26M | $424.29M | $225.87M | $478.56M |
| Return on year-end equity | -32.1% | -17.7% | -37.0% | -33.9% |
| Shares outstanding | 106.25M | 386.38M | 639.86M | 81.38M |
Revenue, most recent five fiscal years
| Fiscal year | Edgewise Therapeutics, Inc. | Standard Biotools Inc. | Geron Corp | Olema Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $85.33M Ended 2025-12-31 | $237.0K Ended 2023-12-31 | n/a |
| 1 year earlier | n/a | $91.01M Ended 2024-12-31 | $596.0K Ended 2022-12-31 | n/a |
| 2 years earlier | n/a | $106.34M Ended 2023-12-31 | $1.39M Ended 2021-12-31 | n/a |
| 3 years earlier | n/a | $97.95M Ended 2022-12-31 | $253.0K Ended 2020-12-31 | n/a |
| 4 years earlier | n/a | $130.58M Ended 2021-12-31 | $460.0K Ended 2019-12-31 | n/a |